Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273112 | 0.81 | LMNA (0.52) | ABCG2ABCB1KDM4ELMNATP53 | |
| SCHEMBL28470333 | 0.80 | LMNA (0.74) | ABCG2ABCB1LMNAMEN1KMT2A | |
| SCHEMBL6089453 | 0.80 | KDM4E (0.51) | ABCG2ABCB1KDM4ELMNATP53 | |
| SCHEMBL5439807 | 0.77 | PKM (0.61) | ABCG2ABCB1KDM4ELMNAMEN1 | |
| SCHEMBL18689299 | 0.74 | ABCG2 (1.00) | ABCG2ABCB1KDM4ERAB9AMAPT | |
| SCHEMBL23116688 | 0.74 | KDM4E (0.56) | ABCG2ABCB1KDM4ELMNAMEN1 | |
| SCHEMBL18689326 | 0.73 | ABCB1 (0.76) | ABCG2ABCB1KDM4ELMNAMEN1 | |
| SCHEMBL21731959 | 0.73 | TP53 (0.55) | ABCG2ABCB1LMNATP53MAPT | |
| SCHEMBL10859605 | 0.73 | ABCG2 (0.54) | ABCG2ABCB1KDM4ELMNAMEN1 | |
| SCHEMBL10856970 | 0.73 | KIF11 (0.54) | ABCG2ABCB1KDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | ABCG2 7/4885ABCB1 20/4885KDM4E 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.